Progress in pharmacogenomics and efficacy prediction of levetiracetam

VernacularTitle:左乙拉西坦的药物基因组学与疗效预测研究进展
Author: Ting WANG ¹ ; Wenqiu YANG ; Yanying YU ; Liling CHEN ; Qian WU ; Yanbing HAN
Author Information

1. 昆明医科大学第一附属医院神经内科　650032
Keywords: Levetiracetam; Pharmacogenomics; Synaptic vesicular protein 2A; Epilepsy; Prediction
From: Chinese Journal of Neurology 2021;54(9):973-978
CountryChina
Language:Chinese
Abstract: Levetiracetam (LEV) is the second generation of broad-spectrum antiepileptic drugs. Compared with other antiepileptic drugs, LEV has unique antiepileptic mechanism, good efficacy and tolerance, and its target is synaptic vesicle protein 2A. With the widespread use of LEV, more and more adverse reactions have been reported, especially mental related adverse reactions. This paper reviewed the research progress of LEV pharmacogenomics related targets, metabolism, adverse reaction related genetic variation and efficacy prediction, so as to provide decision-making for the application of LEV individualized treatment in clinical practice, improve the quality of life of epileptic patients and reduce the disease burden of patients with epilepsy.